Hansen Alexander, Bekeredjian Raffi, Filusch Arthur, Wolf David, Gross Marie-Luise, Mueller Sebastian, Korosoglou Grigorios, Kuecherer Helmut F
Department of Cardiology, University of Heidelberg, Heidelberg, Germany.
J Am Soc Echocardiogr. 2005 Nov;18(11):1213-20. doi: 10.1016/j.echo.2005.08.006.
The aims of the study were to visualize the dynamics of ischemia-reperfusion injury by real-time myocardial contrast echocardiography and to investigate the cardioprotective effects of the novel endothelin-A receptor antagonist BSF 461314. BSF 461314 reduced infarct size by 47% and preserved microvascular integrity. Real-time myocardial contrast echocardiography allowed visualization of postischemic microvascular dysfunction and quantification of cardioprotective effects of selective endothelin antagonism. Blood flow index A x beta was reduced in anterior segments during ischemia compared with baseline (0.06 +/- 0.01 vs 0.98 +/- 0.2 dB/s) but was higher in the BSF 461314 group after 120 minutes of reperfusion (0.7 +/- 0.08 vs 0.3 +/- 0.05 dB/s, P = .015). Therefore, selective endothelin-A receptor antagonism improved microvascular integrity during postischemic reperfusion. Real-time myocardial contrast echocardiography accurately detected changes in microvascular reflow.
Endothelin-1 is a potent vasoconstrictor and elevated in myocardial ischemia. The aims of the study were to examine cardioprotective effects of the novel selective endothelin-A receptor antagonist BSF 461314 and to visualize changes in the microvasculature by real-time myocardial contrast echocardiography (MCE).
A total of 16 open-chest pigs underwent 45 minutes of left anterior descending coronary artery occlusion followed by 120 minutes of reperfusion. A total of 1 mg/kg BSF 461314 or vehicle was given intravenously before reperfusion. Serial MCE was performed to assess changes in myocardial blood flow A x beta and perfusion defect size. Myocardial blood flow was measured by fluorescent microspheres and infarct size was measured by triphenyltetrazolium chloride tissue staining.
Dynamics of infarct size expansion and tissue perfusion were correctly assessed by MCE. A x beta Was reduced in anterior segments during left anterior descending coronary artery occlusion (0.06 +/- 0.01 dB/s) compared with baseline (0.98 +/- 0.2 dB/s), approached higher levels postrecanalization (1.2 +/- 0.1 dB/s), but gradually decreased during reperfusion (0.3 +/- 0.05 dB/s, P < .01). After 120 minutes of reperfusion A (2.1 +/- 0.5 vs 1.0 +/- 0.6 dB, P < .03), beta (0.36 +/- 0.09/s vs 0.21 +/- 0.09/s, P = .01), and A x beta (0.7 +/- 0.08 vs 0.3 +/- 0.05 dB/s, P = .015) in the risk area were higher in the BSF 461314-treated group compared with vehicle indicating preserved myocardial perfusion. Triphenyltetrazolium chloride staining confirmed a 47% reduction in infarct size by BSF 461314.
Selective endothelin-A receptor antagonism improved microvascular integrity during postischemic reperfusion. Real-time MCE allows visual and quantitative evaluation of dynamics of myocardial ischemia-reperfusion injury and monitoring of cardioprotective effects during pharmacologic interventions.
本研究的目的是通过实时心肌对比超声心动图观察缺血再灌注损伤的动态变化,并研究新型内皮素-A受体拮抗剂BSF 461314的心脏保护作用。BSF 461314使梗死面积减少了47%,并保持了微血管的完整性。实时心肌对比超声心动图能够观察缺血后微血管功能障碍,并对选择性内皮素拮抗作用的心脏保护效果进行量化。与基线相比,缺血期间前壁节段的血流指数A×β降低(0.06±0.01对0.98±0.2 dB/s),但在再灌注120分钟后,BSF 461314组的该指数更高(0.7±0.08对0.3±0.05 dB/s,P = 0.015)。因此,选择性内皮素-A受体拮抗作用改善了缺血后再灌注期间的微血管完整性。实时心肌对比超声心动图准确检测到了微血管再灌注的变化。
内皮素-1是一种强效血管收缩剂,在心肌缺血时升高。本研究的目的是研究新型选择性内皮素-A受体拮抗剂BSF 461314的心脏保护作用,并通过实时心肌对比超声心动图(MCE)观察微血管的变化。
总共16只开胸猪接受了45分钟的左前降支冠状动脉闭塞,随后再灌注120分钟。在再灌注前静脉注射1 mg/kg BSF 461314或赋形剂。进行系列MCE以评估心肌血流A×β和灌注缺损大小的变化。通过荧光微球测量心肌血流,通过三苯基四氮唑氯化物组织染色测量梗死面积。
MCE正确评估了梗死面积扩大和组织灌注的动态变化。与基线相比,左前降支冠状动脉闭塞期间前壁节段的A×β降低(0.06±0.01 dB/s)(基线为0.98±0.2 dB/s),再通后接近更高水平(1.2±0.1 dB/s),但在再灌注期间逐渐降低(0.3±0.05 dB/s,P < 0.01)。再灌注120分钟后,BSF 461314治疗组风险区域的A(2.1±0.5对1.0±0.6 dB,P < 0.03)、β(0.36±0.09/s对0.21±0.09/s,P = 0.01)和A×β(0.7±0.08对0.3±0.05 dB/s,P = 0.015)高于赋形剂组,表明心肌灌注得以保持。三苯基四氮唑氯化物染色证实BSF 461314使梗死面积减少了47%。
选择性内皮素-A受体拮抗作用改善了缺血后再灌注期间的微血管完整性。实时MCE能够对心肌缺血再灌注损伤的动态变化进行可视化和定量评估,并在药物干预期间监测心脏保护效果。